Hematologic Malignancy

OSUCCC-James is home to one of the world’s leading hematologic malignancy programs. A transdisciplinary team of internationally-renowned hematologists, oncologists, mid-level practitioners, researchers, nurses and other cancer experts specialize in distinct hematologic malignancies including acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, myeloproliferative disorders, multiple myeloma, Hodgkin’s Disease and non-Hodgkin’s lymphoma.

Our work related to understanding how blood cancers are wired and also identifying promising investigational treatments is supported by millions in ongoing research grants, including multiple grants from the National Cancer Institute and the Leukemia and Lymphoma Society. We are one of two comprehensive leukemia centers in the US that has a Specialized Program of Research Excellence (SPORE). Dozens of clinical trials under way at OSUCCC–James put our physicians and researchers on the leading edge of advances in detecting and treating hematologic malignancies.
Learn about clinical trials, including a promising new drug to treat chronic lymphocytic leukemia, ongoing research and our team of hematologic malignancy experts at the links below.

Clinical Trials
How to Refer

Click here to learn about our Hematology & Medical Oncology Fellowship Program.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu